Keyword: Biotechnology Industry Organization
A Nevada judge denied the drug industry's request for an injunction that would have stopped a new pricing-disclosure law in its tracks.
Top industry lobby groups are challenging a new drug pricing law in Nevada.
Even without U.S. tax reforms expected to spur M&A action, biopharma dealmaking hasn’t slowed down, and nor should industry watchers assume it will.
Executives are worried, big time, with 88% pegging the issue as their biggest challenge.
Marathon’s Emflaza pricing remains in an unwelcome spotlight as eight more senators zero in on the company and its newly approved, $89,000 DMD med.
A new FDA rule that would govern off-label marketing has drugmakers in a minor tizzy—and they're demanding that the agency set its change aside.